Model simulations further suggest that MLST8 may stimulate tumour development and/or progression through promoted activation of both MTOR complexes, a notion in line with published data in colon and prostate cancer [13] and our result that high MLST8 is associated with poorer overall survival in breast cancer patients (Fig 7C). Here, MLST8 is linked to prostate cancer.